Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 3—March 2015
Dispatch

Novel Mutations in K13 Propeller Gene of Artemisinin-Resistant Plasmodium falciparum

Rie IsozumiComments to Author , Haruki Uemura, Isao Kimata, Yoshio Ichinose, John Logedi, Ahmeddin H. Omar, and Akira Kaneko
Author affiliations: Osaka City University, Osaka, Japan (R. Isozumi, I. Kimata, A. Kaneko); Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan (H. Uemura, Y. Ichinose); Ministry of Public Health and Sanitation, Nairobi, Kenya (J. Logedi, A.H. Omar); Karolinska Institutet, Stockholm, Sweden (A. Kaneko)

Cite This Article

Abstract

We looked for mutations in the Plasmodium falciparum K13 propeller gene of an artemisinin-resistant parasite on islands in Lake Victoria, Kenya, where transmission in 2012–2013 was high. The 4 new types of nonsynonymous, and 5 of synonymous, mutations we detected among 539 samples analyzed provide clues to understanding artemisinin-resistant parasites.

The worldwide spread of malaria parasites with resistance to antimalarial drugs has been a serious concern over the past few decades. During the 2000s, Plasmodium falciparum parasites acquired resistance to key drugs, such as chloroquine and sulfadoxine–pyrimethamine, in many malaria-endemic countries, including Kenya (1). Artemisinin-based combination therapy (ACT) has been introduced in most malaria-endemic countries and is the first-line therapy. However, the first clinical cases of artemisinin resistance in western Cambodia were reported in 2008 (2), and P. falciparum with reduced in vivo susceptibility to artesunate in western Cambodia was reported in 2009 (3,4). On the basis of these findings, genome-wide analyses of artemisinin-resistant P. falciparum isolates found strong correlations between a mutant allele in the K13 propeller, in vitro parasite survival rates, and in vivo parasite clearance rates; these correlations indicate that mutations in the K13 propeller (especially C580Y, R539T, and Y439H) are important determinants of artemisinin resistance (5,6). Analysis of parasites from several Cambodian provinces indicated that K13 propeller mutations are rarely observed in samples from provinces without documented resistance but are prevalent in provinces with reported resistance (6,7).

In Kenya, ACT was introduced as first-line therapy for P. falciparum malaria in 2004 (1). However, various types of antimalarial drugs—including chroloquine, sulfadoxine–pyrimethamine, and artemether/lumefantrine—are available for purchase at pharmacies without physicians’ prescriptions. In this study, we describe some K13 propeller mutations of P. falciparum parasites from western Kenya.

The Study

Figure

Thumbnail of Study sites for investigation of K13 propeller gene in Plasmodium falciparum, Mbita District, Kenya, 2012–2013. Insert shows location of study area in Kenya.

Figure. Study sites for investigation of K13 propeller gene in Plasmodium falciparum, Mbita District, Kenya, 2012–2013. Insert shows location of study area in Kenya.

The research was conducted at 4 islands on Lake Victoria (Kibuogi, Ngodhe, Takawiri, Mfangano) and 1 shoreline community of Mbita District (Ungoye) in western Kenya (Figure). In this area, the PfPR2–10 (community P. falciparum parasite rate standardized to the 2- to 10-year age group) was reported in 2009 to be >40% (8). Although in some area of Kenya malaria has decreased, its prevalence remains high in the Lake Victoria basin because of the lake environment (810). In 2009, a total of 50%–70% of households owned insecticide-treated bed nets (11), which substantially reduce the risk for transmission of malaria parasites by providing barriers against mosquitoes. Although malaria is annually more prevalent in the 2 wet seasons (March–June and October–November) (9), in the study sites, it is highly endemic throughout the year.

Filter paper blood spots were collected from participants (Technical Appendix Table 1) during population-wide cross-sectional malaria surveys conducted in February and August 2012 and August 2013 at the 5 study sites. We obtained ethics approval from the Kenyatta National Hospital and the University of Nairobi. All study participants provided informed consent.

Parasitic DNA was extracted from the filter paper (12), and P. falciparum DNA was detected by a mitochondrial DNA-based PCR (13). Sequencing of the K13 propeller gene was attempted on the diagnostic PCR-positive specimens (online Technical Appendix). The prevalence of P. falciparum, as determined by PCR, in the rainy and dry seasons was 7.2%–26.2% and 6.5%–15.5% on the 3 small islands (Kibuogi, Ngodhe, and Takawiri), 47.3% and 31.4% on Mfangano Island, and 38.4% and 41.9%–64.0% in Ungoye, respectively (Table 1).

We successfully analyzed 539 samples for the K13 propeller gene. Nine new types of point mutations were identified among these samples (Table 2). Participants infected with parasites harboring a mutation on the K13 propeller gene are listed in Technical Appendix Table 2. The sequences reported in this study have been deposited in the DDBJ/EMBL/GenBank databases (accession nos.AB936059–AB936067).

Conclusions

We detected 4 novel nonsynonymous and 5 novel synonymous mutations in the highly conserved K13 propeller gene of P. falciparum parasites from western Kenya. Ariey et al. noted that the frequency of mutant alleles strongly correlated with the prevalence of day 3 positivity after ACT treatment in humans in Cambodia and that those mutations reflected positive selection (6). That study found 17 mutant alleles in the K13 propeller gene. Among them, C580Y, R539T, and Y493H were prevalent and strongly related to in vivo delayed parasite clearance. In our study, all the mutations found differed from those reported in Cambodia, and mutant alleles were not always observed in the proceeding seasons, so some mutations could be occasionally introduced. Most of those mutations are not suitable for the life cycle of parasites, and only a few suitable for survival under the conditions of artemisinin selection pressure could be selected.

We observed no identical mutations at >2 of these 5 study sites. Furthermore, only 1 type of mutation, A578S from Mfangano Island, was detected during 2 seasons, whereas other mutations were not observed in the next season, half a year later. Any family relations were not identified among the 4 participants harboring A578S mutation in February 2012 at Mfangano Island. Point mutations can occasionally occur on the P. falciparum K13 propeller gene as a standing variation, but most of the isolates that recently acquired the mutation may disappear because of some fitness disadvantage or the effect of a random genetic drift (14).

Malaria parasites grow and multiply at 2 different biologic stages in humans and mosquitoes. Therefore, isolates with new mutations must adapt to both circumstances. We detected the mutant allele A578S in the K13 propeller gene in 2 consecutive seasons on Mfangano Island. This mutation, which modifies amino acids from being hydrophobic to hydrophilic, is close to the prevalent single nucleotide polymorphism C580Y from Cambodia that is thought to be necessary in protein–protein interactions, which could affect artemisinin susceptibility. The genotype analyses of the parasites from this island are critical to understanding the role of this mutation and ACT efficiency in this geographic area.

Our K13 propeller sequence analysis of P. falciparum parasites from a malaria-endemic area in Kenya did not detect the predicted artemisinin-resistant genotypes, but we observed some temporal substitutions. A limitation of our study was that the sample size was insufficient to specifically provide an understanding of this result. The accumulation of data from this region and from other malaria-endemic areas will increase our understanding of the relationship between the K13 propeller gene and artemisinin resistance. Monitoring these molecular markers and the efficacy of antimalarial drugs is critical for increasing understanding of artemisinin resistance and predicting its spread. This study identified clues that are essential in understanding artemisinin-resistant parasites.

Dr. Isozumi is an assistant professor in the Department of Medicine at Osaka City University. Her research interests include the microbiology and molecular mechanisms of drug resistance in various microorganisms.

Top

Acknowledgments

We thank Masatsugu Kimura, Chim Chan, Zulkarnain Md Idris, and James Kongre for the field survey.

This research was funded by the cooperative research grants (2013-A-7 and 2014-A-18) of the Institute of Tropical Medicine to R.I., Japan Society for Promotion of Science grants (24390141and 26257504) to A.K., Health Labour Science Research Grant to A.K., and Japanese Society for the Promotion of Science Core-to-Core Program B, Asia-Africa Science Platforms to A.K.

Top

References

  1. Flegg  JA, Metcalf  CJ, Gharbi  M, Venkatesan  M, Shewchuk  T, Hopkins Sibley  C, Trends in antimalarial drug use in Africa. Am J Trop Med Hyg. 2013;89:85765 . DOIPubMed
  2. Noedl  H, Se  Y, Schaecher  K, Smith  BL, Socheat  D, Fukuda  MM, Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:261920 . DOIPubMed
  3. Dondorp  AM, Nosten  F, Yi  P, Das  D, Phyo  AP, Tarning  J, Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:45567 .PubMed
  4. Dondorp  AM, Fairhurst  RM, Slutsker  L, Macarthur  JR, Breman  JG, Guerin  PJ, The threat of artemisinin-resistant malaria. N Engl J Med. 2011;365:10735 . DOIPubMed
  5. Miotto  O, Almagro-Garcia  J, Manske  M, Macinnis  B, Campino  S, Rockett  KA, Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013;45:64855 . DOIPubMed
  6. Ariey  F, Witkowski  B, Amaratunga  C, Beghain  J, Langlois  AC, Khim  N, A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:505 . DOIPubMed
  7. Plowe  CV. Malaria: resistance nailed. Nature. 2014;505:301 . DOIPubMed
  8. Noor  AM, Gething  PW, Alegana  VA, Patil  AP, Hay  SI, Muchiri  E, The risks of malaria infection in Kenya in 2009. BMC Infect Dis. 2009;9:180 . DOIPubMed
  9. Minakawa  N, Dida  GO, Sonye  GO, Futami  K, Njenga  SM. Malaria vectors in Lake Victoria and adjacent habitats in western Kenya. PLoS ONE. 2012;7:e32725 . DOIPubMed
  10. O’Meara  WP, Bejon  P, Mwangi  TW, Okiro  EA, Peshu  N, Snow  RW, Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet. 2008;372:155562 . DOIPubMed
  11. Zhou  G, Afrane  YA, Vardo-Zalik  AM, Atieli  H, Zhong  D, Wamae  P, Changing patterns of malaria epidemiology between 2002 and 2010 in western Kenya: the fall and rise of malaria. PLoS ONE. 2011;6:e20318 . DOIPubMed
  12. Sakihama  N, Mitamura  T, Kaneko  A, Horii  T, Tanabe  K. Long PCR amplification of Plasmodium falciparum DNA extracted from filter paper blots. Exp Parasitol. 2001;97:504 . DOIPubMed
  13. Isozumi  R, Fukui  M, Kaneko  A, Chan  CW, Kawamoto  F, Kimura  M. Improved detection of malaria cases in island settings of Vanuatu and Kenya by PCR that targets the Plasmodium mitochondrial cytochrome c oxidase III (cox3) gene. Parasitol Int. 2014 Sep 22 [Epub ahead of print]. PubMed
  14. Chang  HH, Moss  EL, Park  DJ, Ndiaye  D, Mboup  S, Volkman  SK, Malaria life cycle intensifies both natural selection and random genetic drift. Proc Natl Acad Sci U S A. 2013;110:2012934 . DOIPubMed

Top

Figure
Tables

Top

Cite This Article

DOI: 10.3201/eid2103.140898

Table of Contents – Volume 21, Number 3—March 2015

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Rie Isozumi, Department of Medicine, Osaka City University, 1-4-3, Asahimachi, Osaka Abenoku, Osaka, 545-8585, Japan

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: February 18, 2015
Page updated: February 18, 2015
Page reviewed: February 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external